在头癌中新兴的EGFR向疗法:一篇评论
Woochan Hwang1,2, Jong Seok Ahn1,2, Hyun Ae Jung1,3
1Division of Hematology-Oncology, Department of Medicine, Massachusetts General Hospital, Boston.
JAMA oncology
|September 25, 2025
概括
针对表皮生长因子受体 (EGFR) 的新疗法对晚期头支状细胞癌 (HNSCC) 显示出前途. 然而,在人类乳头瘤病毒 (HPV) 阳性HNSCC中,疗效有限,需要进一步研究.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 头部和部状细胞癌 (HNSCC) 是一个主要的健康问题,晚期的治疗选择有限.
- 皮表皮生长因子受体 (EGFR) 在HNSCC中经常过度表达,使其成为关键的治疗点.
- 目前针对EGFR的治疗方法在HNSCC中提供了适度的临床益处.
研究的目的:
- 审查针对HNSCC的EGFR向治疗的不断变化的格局.
- 介绍新型EGFR向剂的生物学理由和早期试验结果.
- 讨论未来改善HNSCC治疗疗效的方向.
主要方法:
- 对HNSCC中EGFR向治疗的当前文献的综述.
- 对新型治疗剂的分析,包括双特异性抗体,抗体-药物合物,免疫细胞参与剂和适应性细胞疗法.
- 对新兴EGFR向方法的临床试验数据的检查.
主要成果:
- 目前正在研究基于 cetuximab 的组合疗法和新药.
- 早期阶段的试验显示了新的治疗策略的潜力.
- 针对EGFR的疗法在人类乳头瘤病毒 (HPV) 阳性HNSCC.中显示出效率降低.
结论:
- 新兴的组合方法和新型EGFR向剂为先进的HNSCC提供了新的希望.
- 未来的进展需要对瘤生物学有更深入的了解,以及创新的策略来减轻毒性.
- 在越来越多的HPV阳性HNSCC患者中提高疗效至关重要.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K


